Bioprocess for the manufacturing of affordable pharmaceuticals to prevent and treat cancers, obesity and age-related diseases

用于生产预防和治疗癌症、肥胖症和年龄相关疾病的负担得起的药物的生物工艺

• 批准号: 133774
• 金额: $ 19.44万
• 依托单位: VIDERA SERVICES LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133774
• 关键词: Bioprocess; manufacturing; affordable; pharmaceuticals; prevent

"The population over the age of 65 is predicted to double by 2070, increasing the incidence of age-related diseases and will put additional pressure on the medical and societal care infrastructure. Long term, cost-effective strategies are required to decrease the prevalence (and societal burden) of obesity and its associated co-morbidities, and to reduce the incidence and impact of age-related disorders and cancer on the quality of life of an ageing population.Conjugated linoleic acid (CLA) refers to a mixture of various forms (isomers) of the omega-6 unsaturated fatty acid, linoleic acid. The safety and health benefits of CLA are documented in \>4000 scientific publications, and \>100 human studies have been published. It is an essential nutrient not produced by the body and not present in sufficient amounts in food, thus requiring dietary supplementation.CLA is commercially produced by chemical conversion of linoleic acid or oils rich in linoleic acid (sunflower and saffron) as a mixture of four isomers that cannot be separated cost-effectively. The different isomers may exhibit additive, independent or antagonistic physiological effects. Pure isomers are not commercially available; thus, most studies on humans and animals were performed with isomer mixtures, which obscured the results and hinders elucidation of the mechanisms through which the individual isomers exert their health effects.One of these CLA isomers has potent anti-obesity, anti-cancer, anti-osteoporosis and anti-atherosclerosis activity, while improving energy balance and maintaining lean muscle. However, its beneficial effects are reduced in the presence of the other isomers which may also have undesirable effects. Thus, for medical purposes, this desired isomer in pure form is urgently required as a low-cost preventative and curative treatment for a wide variety of metabolic disorders.This project will investigate a novel route to produce these CLA isomers in pure form as a first step to provide cost-effective treatments for cancer, obesity and age-related disorders. VideraBio, a UK-based SMME, and BrisSynBio (a UK Synthetic Biology Centre) will collaborate to deliver this cutting-edge innovation."

“预计到2070年，65岁以上的人口将翻一番，这将增加与年龄有关的疾病的发病率，并将给医疗和社会护理基础设施带来额外的压力。”需要采取具有成本效益的长期战略，以降低肥胖及其相关合并症的患病率（和社会负担），并减少与年龄有关的疾病和癌症对老龄化人口生活质量的发病率和影响。共轭亚油酸（CLA）是指各种形式的混合物（异构体）的ω -6不饱和脂肪酸，亚油酸。4000份科学出版物记载了CLA的安全和健康益处，并发表了100份人体研究报告。它是一种必需的营养物质，不是由身体产生的，在食物中也没有足够的量，因此需要膳食补充。CLA是由亚油酸或富含亚油酸的油（向日葵和藏红花）作为四种异构体的混合物进行化学转化而商业化生产的，这些异构体不能经济有效地分离。不同的异构体可能表现出加性的、独立的或拮抗的生理作用。纯异构体在商业上是买不到的；因此，大多数对人类和动物的研究都是用异构体混合物进行的，这掩盖了结果，阻碍了阐明单个异构体发挥其健康影响的机制。这些CLA异构体之一具有有效的抗肥胖，抗癌，抗骨质疏松和抗动脉粥样硬化活性，同时改善能量平衡和保持瘦肌肉。然而，在其他异构体存在的情况下，其有益效果会降低，这些异构体也可能具有不良影响。因此，出于医学目的，迫切需要这种纯形式的理想异构体作为各种代谢紊乱的低成本预防和治疗方法。该项目将研究一种新的途径，以纯形式生产这些CLA异构体，作为为癌症、肥胖和年龄相关疾病提供经济有效治疗的第一步。VideraBio是一家总部位于英国的中小企业，而BrisSynBio（英国合成生物学中心）将合作提供这一尖端创新。”